Is Psyence Biomedical Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Psyence Biomedical Ltd (PBM) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Psyence Biomedical Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Psyence Biomedical Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Psyence Biomedical Ltd?

Muslim investors may consider investing in Psyence Biomedical Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Psyence Biomedical Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Psyence Biomedical Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Psyence Biomedical Ltd updated?

The Shariah compliance status of Psyence Biomedical Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Psyence Biomedical Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Psyence Biomedical Ltd?

You can check the latest Shariah compliance status of Psyence Biomedical Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

PBM Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: December 04, 2025

Report Source: 2026 2nd Quarter Report

Psyence Biomedical Ltd. Stock Analysis PBM

United States Health Care Nano Cap Report: Q2, 2026

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Key Statistics of Psyence Biomedical Ltd (PBM)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$4.80$5.34

Today's Open

$5.04

Volume

137.24K

P/E Ratio (TTM)

5.09

52 Week Range

$1.92$468.38

Market Cap

6.25M

Avg. Volume

6.85M

Dividend Yield

Financial Metrics & Statements of Psyence Biomedical Ltd (PBM)

FAQ's for Psyence Biomedical Ltd (PBM)

According to Musaffa’s Shariah screening methodology, Psyence Biomedical Ltd (PBM) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.